Call Toll Free:
1 (855) MEDVIN-1
Gout Trials
The study utilizes an already FDA approved drug for the treatment of Gout that helps lower the Uric Acid levels in patients. The patients DO NOT need to be on a Gout medication. Gout is a type of inflammatory arthritis caused by the accumulation of urate crystals in the joints, resulting in severe pain, swelling, and inflammation. This study aims to assess the potential of new therapies in managing gout symptoms and improving patient outcomes. The sponsor will provide Methotrexate medication to participants during the study.
Participation Criteria
This is your Product section paragraph. It’s an ideal place to showcase the types of products available, and underline any important or unique features.
Participating Locations
-
Covina
-
Whittier
-
Riverside
-
Tujunga
-
Temecula
-
Menifee
-
Earn up to $ 4,800 total
-
$100 per visit for a total of 48 visits
Compensation
-
FDA approved drug (No Placebo involved) all subject will receive active medication.
Medications
-
16-month study (Double-blind period 23 weeks, followed by Open-label extension week 24 - week 44).
Durations
Trial Details
Gout Trials
The study utilizes an already FDA approved drug for the treatment of Gout that helps lower the Uric Acid levels in patients. The patients DO NOT need to be on a Gout medication. Gout is a type of inflammatory arthritis caused by the accumulation of urate crystals in the joints, resulting in severe pain, swelling, and inflammation. This study aims to assess the potential of new therapies in managing gout symptoms and improving patient outcomes. The sponsor will provide Methotrexate medication to participants during the study.
Participation Criteria
-
This is your Product section paragraph. It’s an ideal place to showcase the types of products available, and underline any important or unique features.
Participating Locations
-
Covina
-
Whittier
-
Riverside
-
Tujunga
-
Temecula
-
Menifee
-
Earn up to $ 4,800 total
-
$100 per visit for a total of 48 visits
Compensation
-
FDA approved drug (No Placebo involved) all subject will receive active medication.
Medications
-
16-month study (Double-blind period 23 weeks, followed by Open-label extension week 24 - week 44).
